These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 23981659)

  • 1. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
    Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
    Kawazoe M; Kaneko K; Shikano K; Kusunoki N; Nanki T; Kawai S
    Clin Rheumatol; 2018 Aug; 37(8):2169-2178. PubMed ID: 28551822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
    Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
    Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
    Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
    Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin levels and changes in bone metabolism after bariatric surgery.
    Muschitz C; Kocijan R; Marterer C; Nia AR; Muschitz GK; Resch H; Pietschmann P
    J Clin Endocrinol Metab; 2015 Mar; 100(3):891-901. PubMed ID: 25490275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of bone mineral density in patients receiving glucocorticoid replacement for Addison's disease.
    Furman K; Gut P; Sowińska A; Ruchała M; Fichna M
    Endocrine; 2024 May; 84(2):711-719. PubMed ID: 38334892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
    van Lierop AH; Hamdy NA; Hamersma H; van Bezooijen RL; Power J; Loveridge N; Papapoulos SE
    J Bone Miner Res; 2011 Dec; 26(12):2804-11. PubMed ID: 21786318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes.
    Brabnikova Maresova K; Pavelka K; Stepan JJ
    Calcif Tissue Int; 2013 Apr; 92(4):354-61. PubMed ID: 23247536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis.
    Peng J; Dong Z; Hui Z; Aifei W; Lianfu D; Youjia X
    BMC Musculoskelet Disord; 2021 May; 22(1):480. PubMed ID: 34034718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
    Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
    Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus.
    Gaudio A; Privitera F; Battaglia K; Torrisi V; Sidoti MH; Pulvirenti I; Canzonieri E; Tringali G; Fiore CE
    J Clin Endocrinol Metab; 2012 Oct; 97(10):3744-50. PubMed ID: 22855334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women.
    Fassio A; Adami G; Benini C; Vantaggiato E; Saag KG; Giollo A; Lippolis I; Viapiana O; Idolazzi L; Orsolini G; Rossini M; Gatti D
    Bone; 2019 Jun; 123():191-195. PubMed ID: 30910600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
    Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
    Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.
    Gatti D; Viapiana O; Adami S; Idolazzi L; Fracassi E; Rossini M
    Bone; 2012 Mar; 50(3):739-42. PubMed ID: 22178539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.